The Effect of Mill Type on Two Dry-Granulated Placebo Formulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Mill Type on Two Dry-Granulated Placebo Formulations
The authors evaluate the effect of various mill types on particle-size distribution, flowability, tabletability, and compactibility.


Pharmaceutical Technology
Volume 32, Issue 11, pp. 72-86


Table VI: Microcrystalline cellulose–dibasic calcium phosphate compression properties.
Tableting. MCC–DCP formulation. Tablets were compressed and characterized for weight, thickness, and hardness. The mean weight values and corresponding relative standard deviations (RSDs) are listed in Table VI. Weight variation was below the desired RSD of 2.0% for all the conventional mill types. The two Gran-U-Lizer runs had slightly higher RSDs, but they were still below the 6.0% RSD allowed by US Pharmacopeia criteria.


Figure 7: Tabletability profile for microcrystalline cellulose–dibasic calcium phosphate formulation. (AUTHORS)
The tabletability profile (see Figure 7) shows that the tensile strength of all the tablet lots easily exceeded the desirable target crushing strength of 2.0 MPa. Also, the compactibility profile (see Figure 8) shows that the tablets achieved a tensile strength of 2.0 MPa at a solid fraction of approximately 0.80–0.81, indicating that strong bonds were formed at relatively low solid fractions. All formulations performed well, regardless of the mill type used or difference in particle-size distribution.


Figure 8: Compactibility profile for microcrystalline cellulose–dibasic calcium phosphate formulation. (AUTHORS)
MCC–lactose formulation. Weight variation for all the mill types was well below an RSD of 2.0%, and weight control is not considered a problem, regardless of the difference in particle-size distribution. Weight, thickness, and hardness values are listed in Table VII.


Figure 9: Tabletability profile for microcrystalline cellulose–lactose formulation. (AUTHORS)
The tabletability plot (see Figure 9) shows that the tensile strength of all the lots easily exceeded the desirable target of 2.0 MPa. However, the Gerteis milled formulation performed the best of all the lots. Its maximum tablet-crushing strength was ~0.5 MPa higher than the other mill types. The compactibility profile (see Figure 10) shows that the tablets achieved a tensile strength of 2.0 MPa when compaction was at a solid fraction of approximately 0.86–0.88. All formulations performed similarly, regardless of the mill type used and the difference in particle-size distribution, except for the Gerteis milled granulation.

Conclusions


Figure 10: Compactibility profile for microcrystalline cellulose–lactose formulation. (AUTHORS)
In general, the mill type used and resulting granulation particle-size distribution did not greatly influence the tabletability or compactibility of either placebo formulation. The MCC–DCP formulation demonstrated excellent tableting and compaction properties, regardless of the mill type used. Although a higher RSD for the tablet weight values using the Gran-U-Lizer was observed, it is considered acceptable. Adjustments to the Gran-U-Lizer parameters might make the particle-size distribution slightly lower and improve the granulation, tableting, and compaction performance.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here